Skip to content

Keganliyan oral liquid in the treatment of acute pharyngitis (externally induced wind-heat syndrome) : a randomized, double-blind, placebo-parallel, multicenter clinical study

Keganliyan oral liquid in the treatment of acute pharyngitis (externally induced wind-heat syndrome) : a randomized, double-blind, placebo-parallel, multicenter clinical study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005711
Enrollment
Unknown
Registered
2022-03-14
Start date
2021-10-20
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pharyngitis

Interventions

Control Group:Kegan Liyan Oral Solutio Simulator
Test Group:Kegan Liyan Oral Solutio

Sponsors

Guangdong Provincial Hospital of traditional Chinese medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) meet the diagnostic criteria of acute pharyngitis of Western Medicine; (2) meet the diagnostic criteria of wind-heat Syndrome caused by exogenous pathogenic factors of Traditional Chinese Medicine; (3) body temperature =38.5 °c; (4) Pain Vas =4 points; (5) course of Disease =48 hours; (6) age between 18 and 65 years; (7) sign voluntary informed consent.

Exclusion criteria

Exclusion criteria: (1) patients with NCP positive for nucleic acid or suspected positive for imaging; (2) patients with suppurative Tonsillitis, pneumonia, bronchitis, otitis media, Herpangina, viral myocarditis, acute nephritis, rheumatic joints and other diseases; (3) as a result of measles, scarlet fever, influenza and Agranulocytosis, infectious mononucleosis, leukemia and other pharyngeal symptoms or inflammation; (4) white blood cell count (WBC)=10 * 10 ^ 9/l; (5) those who have used other Chinese and Western medicine for this disease or need to take antibiotics for other diseases within 24 hours; (6) patients with severe primary diseases of heart, cerebral vessels and hemopoietic system, in which AST, ALT > 1.5 n (n is the upper limit of normal value) , serum creatinine (CR) > the upper limit of normal value; patients with malignant tumor; (7) patients with neurological and mental disorders who can not cooperate, or unwilling to cooperate; (8) Allergic Constitution or allergic history to more than two drugs or known ingredients of the drug; (9) pregnant and expectant pregnant or lactating women; (10) participated in other clinical trials in the last 3 months; (11) the researchers did not consider it appropriate to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frame
Total disease response rate;

Secondary

MeasureTime frame
TCM syndrome score change value;Cough VAS score changes;Single symptom score change value;VAS score of pharyngeal pain;Time of onset of sore throat;Time for sore throat to disappear/Disappearance rate of sore throat;Time for complete fever reduction;Area under the pharyngeal VAS score curve;Use of palliative drugs;

Countries

China

Contacts

Public ContactBaijian Wu

Guangzhou WLK Pharmaceutical Co. LTD

Wbj81@163.com18620968121

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026